Wedmont Private Capital Sells 155 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wedmont Private Capital trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,183 shares of the medical research company’s stock after selling 155 shares during the period. Wedmont Private Capital’s holdings in Thermo Fisher Scientific were worth $1,184,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in TMO. WINTON GROUP Ltd acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $332,000. Fairfield Financial Advisors LTD bought a new position in Thermo Fisher Scientific during the second quarter worth $93,000. Waycross Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 12.6% in the second quarter. Waycross Partners LLC now owns 25,014 shares of the medical research company’s stock valued at $13,833,000 after purchasing an additional 2,791 shares during the last quarter. Wealth Dimensions Group Ltd. lifted its stake in shares of Thermo Fisher Scientific by 8.6% during the 2nd quarter. Wealth Dimensions Group Ltd. now owns 402 shares of the medical research company’s stock worth $222,000 after buying an additional 32 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Thermo Fisher Scientific by 1.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,740,482 shares of the medical research company’s stock valued at $962,482,000 after buying an additional 20,075 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TMO shares. TD Cowen boosted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Barclays decreased their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Stephens started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective for the company. Finally, Morgan Stanley decreased their target price on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research report on Monday. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock valued at $25,954,465 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Up 2.5 %

Shares of Thermo Fisher Scientific stock opened at $555.91 on Tuesday. The firm has a market capitalization of $212.64 billion, a PE ratio of 34.85, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm’s 50 day moving average is $529.92 and its 200 day moving average is $568.10. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company earned $5.69 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.